TROG 02.03 - BLADDER (Phase III) - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

Primary Sponsor

Urological Society of Australasia

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Dr Kumar Gogna, QRI Mater Centre, QLD

Trial Contact

Kumar Gogna

Clinical Trial Registration

Registration Link

Tour de Cure grants for TROG Cancer Research trials

9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital

Earlybird registration closes 26 January.

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Randomised phase III trial of radical chemo/radiotherapy vs radiotherapy alone in the definitive management of localised muscle invasive TCC of the urinary bladder

TROG 03.01 – Oesophagus

TROG 11.A – ANROTAT

Related Post

Tour de Cure grants support two valuable TROG trials

GenesisCare Foundation $300,000 donation to support TROG work